Haemonetics (HAE) Capital Expenditures (2009 - 2026)

Haemonetics has reported Capital Expenditures for 18 years, with the latest figure at $7.9 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 110.6% year-over-year to $7.9 million in Q2 2026; TTM through Jun 2026 was $36.9 million, a 1.19% decrease from a year earlier, with the FY2026 full-year figure at $32.8 million, down 16.54% from the prior year.
• Capital Expenditures was $7.9 million for Q2 2026 at Haemonetics, down from $17.7 million in the prior quarter.
• The five-year high for Capital Expenditures was $93.1 million in Q2 2023, with the low at $3.8 million in Q2 2025.
• Average Capital Expenditures over 5 years is $19.5 million, with a median of $9.4 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures surged 226.65% in 2022, then tumbled 92.82% in 2024.
• Over 5 years, Capital Expenditures stood at $16.8 million in 2022, then declined by 13.07% to $14.6 million in 2023, then plunged by 41.65% to $8.5 million in 2024, then decreased by 25.71% to $6.3 million in 2025, then rose by 24.52% to $7.9 million in 2026.
• The last three Capital Expenditures figures came in at $7.9 million (Q2 2026), $17.7 million (Q1 2026), and $6.3 million (Q4 2025), per Business Quant data.